T. E. Owan, D. O. Hodge, R. M. Herges, S. J. Jacobsen, V. L. Roger et al., Trends in prevalence and outcome of heart failure with preserved ejection fraction, N Engl J Med, vol.355, pp.251-259, 2006.

J. Butler, G. C. Fonarow, M. R. Zile, C. S. Lam, L. Roessig et al., Developing therapies for heart failure with preserved ejection fraction: current state and future directions, JACC Heart Fail, vol.2, pp.97-112, 2014.

S. Ather, W. Chan, B. Bozkurt, D. Aguilar, K. Ramasubbu et al., Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction, J Am Coll Cardiol, vol.59, pp.998-1005, 2012.

W. J. Paulus and C. Tschope, A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation, J Am Coll Cardiol, vol.62, pp.263-271, 2013.

C. Franssen, S. Chen, A. Unger, H. I. Korkmaz, D. Keulenaer et al., Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction, JACC: Heart Failure, vol.4, pp.312-324, 2016.

J. P. Eiserich, S. Baldus, M. L. Brennan, W. Ma, C. Zhang et al., Myeloperoxidase, a leukocyte-derived vascular no oxidase, Science, vol.296, pp.2391-2394, 2002.

F. Leyva, T. P. Chua, S. D. Anker, and A. J. Coats, Uric acid in chronic heart failure: a measure of the anaerobic threshold, Metabolism, vol.47, pp.1156-1159, 1998.

E. C. Von-leitner, A. Klinke, D. Atzler, J. L. Slocum, N. Lund et al., Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase, Circulation, vol.124, pp.2735-2745, 2011.

D. Lau, H. Mollnau, J. P. Eiserich, B. A. Freeman, A. Daiber et al., Myeloperoxidase mediates neutrophil activation by association with cd11b/cd18 integrins, Proc Natl Acad Sci U S A, vol.102, pp.431-436, 2005.

S. Wang, R. Song, Z. Wang, Z. Jing, S. Wang et al., S100a8/a9 in inflammation, Front Immunol, vol.9, p.1298, 2018.

W. H. Tang, M. L. Brennan, K. Philip, W. Tong, S. Mann et al., Plasma myeloperoxidase levels in patients with chronic heart failure, Am J Cardiol, vol.98, pp.796-799, 2006.

Y. Michowitz, S. Kisil, H. Guzner-gur, A. Rubinstein, D. Wexler et al., Usefulness of serum myeloperoxidase in prediction of mortality in patients with severe heart failure, Isr Med Assoc J, vol.10, pp.884-888, 2008.

W. H. Tang, W. Tong, R. W. Troughton, M. G. Martin, K. Shrestha et al., Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure, J Am Coll Cardiol, vol.49, pp.2364-2370, 2007.

A. T. Askari, M. Brennan, X. Zhou, J. Drinko, A. Morehead et al., Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction, J Exp Med, vol.197, pp.615-624, 2003.

T. Reichlin, T. Socrates, P. Egli, M. Potocki, T. Breidthardt et al., Use of myeloperoxidase for risk stratification in acute heart failure, Clin Chem, vol.56, pp.944-951, 2010.

E. Donal, L. H. Lund, C. Linde, M. Edner, S. Lafitte et al., Rationale and design of the Karolinska-Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction, Eur J Heart Fail, vol.11, pp.198-204, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00911681

E. Schwedhelm, J. Tan-andresen, R. Maas, U. Riederer, F. Schulze et al., Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma, Clin Chem, vol.51, pp.1268-1271, 2005.

X. Luo, N. Cai, and Z. Cheng, Determination of uric acid in plasma by LC-MS/MS and its application to an efficacy evaluation of recombinant urate oxidase, Anal Sci, vol.29, pp.709-713, 2013.

A. S. Levey, L. A. Stevens, C. H. Schmid, Y. L. Zhang, A. F. Castro et al., A new equation to estimate glomerular filtration rate, Ann Intern Med, vol.150, pp.604-612, 2009.

J. J. Mcmurray, S. Adamopoulos, S. D. Anker, A. Auricchio, M. Bohm et al., Esc guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC, Eur Heart J, vol.33, pp.1787-1847, 2012.

S. F. Nagueh, O. A. Smiseth, C. P. Appleton, . Byrd-bf-3rd, H. Dokainish et al., Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, J Am Soc Echocardiogr, vol.29, pp.277-314, 2016.

R. Raphael, D. Purushotham, C. Gastonguay, M. A. Chesnik, W. M. Kwok et al., Combining patient proteomics and in vitro cardiomyocyte phenotype testing to identify potential mediators of heart failure with preserved ejection fraction, J Transl Med, vol.14, p.18, 2016.

M. Reina-couto, J. Carvalho, M. J. Valente, L. Vale, J. Afonso et al., Impaired resolution of inflammation in human chronic heart failure, Eur J Clin Invest, vol.44, pp.527-538, 2014.

K. B. Shah, W. J. Kop, R. H. Christenson, D. B. Diercks, D. Kuo et al., Lack of diagnostic and prognostic utility of circulating plasma myeloperoxidase concentrations in patients presenting with dyspnea, Clin Chem, vol.55, pp.59-67, 2009.

V. Rudolph, R. P. Andrie, T. K. Rudolph, K. Friedrichs, A. Klinke et al., Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation, Nat Med, vol.16, pp.470-474, 2010.

P. Kruzliak, J. Novak, M. Novak, and G. J. Fodor, Role of calprotectin in cardiometabolic diseases, Cytokine Growth Factor Rev, vol.25, pp.67-75, 2014.

C. S. Lam and L. H. Lund, Microvascular endothelial dysfunction in heart failure with preserved ejection fraction, Heart, vol.102, pp.257-259, 2016.

S. J. Shah, C. Lam, S. Svedlund, A. Saraste, C. Hage et al., Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF, Eur Heart J, vol.39, pp.3439-3450, 2018.

L. Rocca, G. , D. Stefano, A. Eleuteri, E. Anzalone et al., Oxidative stress induces myeloperoxidase expression in endocardial endothelial cells from patients with chronic heart failure, Basic Res Cardiol, vol.104, pp.307-320, 2009.

O. Gedikli, A. Kiris, Y. Hosoglu, C. Karahan, and S. Kaplan, Serum myeloperoxidase level is associated with heart-type fatty acid-binding protein but not troponin T in patients with chronic heart failure, Med Princ Pract, vol.24, pp.42-46, 2015.

M. Hansson, I. Olsson, and W. M. Nauseef, Biosynthesis, processing, and sorting of human myeloperoxidase, Arch Biochem Biophys, vol.445, pp.214-224, 2006.

S. Baldus, J. P. Eiserich, A. Mani, L. Castro, M. Figueroa et al., Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration, J Clin Investig, vol.108, pp.1759-1770, 2001.

N. Cantu-medellin and E. E. Kelley, Xanthine oxidoreductase-catalyzed reactive species generation: a process in critical need of reevaluation, Redox Biol, vol.1, pp.353-358, 2013.

L. K. Stamp, R. Turner, I. S. Khalilova, M. Zhang, J. Drake et al., Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia, Rheumatology (Oxford), vol.53, pp.1958-1965, 2014.

R. Turner, S. O. Brennan, L. V. Ashby, N. Dickerhof, M. R. Hamzah et al., Conjugation of urate-derived electrophiles to proteins during normal metabolism and inflammation, J Biol Chem, vol.293, pp.19886-19898, 2018.

J. M. Hare, B. Mangal, J. Brown, C. Fisher, R. Freudenberger et al., Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study, J Am Coll Cardiol, vol.51, pp.2301-2309, 2008.

M. M. Givertz, K. J. Anstrom, M. M. Redfield, A. Deswal, H. Haddad et al., NHLBI Heart Failure Clinical Research Network. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EX-ACT-HF) study, Circulation, vol.131, pp.1763-1771, 2015.

L. Tamariz, A. Harzand, A. Palacio, S. Verma, J. Jones et al., Uric acid as a predictor of all-cause mortality in heart failure: a meta-analysis, Congest Heart Fail, vol.17, pp.25-30, 2011.

T. Shimizu, A. Yoshihisa, Y. Kanno, M. Takiguchi, A. Sato et al., Relationship of hyperuricemia with mortality in heart failure patients with preserved ejection fraction, Am J Physiol Heart Circ Physiol, vol.309, pp.1123-1129, 2015.

L. Manzano, D. Babalis, M. Roughton, M. Shibata, S. D. Anker et al., Predictors of clinical outcomes in elderly patients with heart failure, Eur J Heart Fail, vol.13, pp.528-536, 2011.

H. Persson, D. E. Lund, L. H. Matan, D. Oger, E. Hage et al., Importance of structural heart disease and diastolic dysfunction in heart failure with preserved ejection fraction assessed according to the ESC guidelines-a substudy in the Ka (Karolinska) Ren (Rennes) study, Int J Cardiol, vol.274, pp.202-207, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01935766

, MPO-dependent stress in HFpEF